An observational study in Type 1 Diabetes Mellitus and Genetic Predisposition to Disease, sponsored by Pediatric Clinical Research Platform. Recruiting at 1 site in Switzerland. Open to participants aged 0 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.
Sponsored by Pediatric Clinical Research Platform · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 7 that started in 2023, is one of 18 observational ones, and was the 60th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
DCB Research AG · Sites in Switzerland
Ages 18–40 · Women only
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
University of Bern · Sites in Switzerland
Ages 18–65
University Hospital, Geneva · Sites in Switzerland
Ages 2–18 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 0 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
Pediatric Clinical Research Platform is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Pediatric Clinical Research Platform has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study consists of performing cluster analysis to decipher underlying disease mechanisms of type 1 diabetes in children and young adults.
To this end, we will combine clinical, laboratory, genetic, transcriptomic, and metabolomic datasets of an extensively phenotyped cohort of children and young adults with type 1 diabetes. We will also assess the risk for cardiovascular diseases in this most vulnerable diabetes cohort.
Children, adolescents, and young adults followed at the pediatric diabetology unit of the University Hospital of Geneva.
Controls Children, adolescents, and young adults coming for a routine blood sample at University Hospital of Geneva
Inclusion Criteria (Type 1 Diabetic patients):
Exclusion Criteria (Type 1 Diabetic patients):
Inclusion Criteria (Controls):
Exclusion Criteria (Controls):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 patients followed in pediatric diabetology at the university hospital of Geneva: a cohort
Genetic: Genome sequencing
50 control patients
Genetic: Genome sequencing
100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed. For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis.
Also known as: Lipidomic, Metabolomic, Transcriptomic, Mixed meal tolerance test
Cluster analysis to decipher underlying mechanisms of type 1 diabetes
We will combine clinical, laboratory, genetic, transcriptomic, and metabolomic datasets of an extensively phenotyped cohort of type 1 diabetes patients (Children and young adults). We will create clinical and genetic correlates with the following clinical parameters: Age at diabetes onset (years), disease duration (years), BMI (kg/m2), diabetes autoantibodies, C-peptide level (pmol/l) and decline over time, HbA1c (%), insulin dose (U/kg/d), ketoacidosis at disease onset (y/n), lipid levels (Total cholesterol, triglycerides, HLD, LDL, Lipoprotein(a)), macro- and microvascular complications, ethnicity, family history for diabetes, associated autoimmune diseases (e.g., autoimmune thyroiditis or celiac disease) and mixed meal tolerance test.
Time frame: blood sampling and analyses
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 36 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pediatric Clinical Research Platform